Objective Postsplenectomy sepsis (PSS) and overwhelming postsplenectomy infection (OPSI) following splenectomy or the development of hyposplenism are associated with a high mortality rate. The presence of Howell-Jolly bodies (HJBs) in peripheral erythrocytes is attracting attention as a parameter of hyposplenism. To date, whether HJBs appear following partial splenic embolization (PSE) has not been investigated. Therefore, we examined the prevalence of HJBs in patients who have undergone PSE. Methods Whether HJBs were present in 95 patients who underwent PSE between November 2007 and August 2012 was assessed.
Introduction
Postsplenectomy sepsis (PSS) and overwhelming postsplenectomy infection (OPSI) following splenectomy or the development of hyposplenism are associated with a high mortality rate (1) (2) (3) . HJBs are inclusion bodies present in erythrocytes that stain with May-Giemsa and are not normally observed in healthy persons, although they are seen in some patients with blood disorders or functional asplenia and those treated with splenectomy (4) (5) (6) .
The presence of Howell-Jolly bodies (HJBs) in peripheral erythrocytes, in particular, is attracting attention as a parameter of hyposplenism (7, 8) .
Recently, splenectomy and partial splenic embolization have been used to achieve prolonged improvement of thrombocytopenia caused by portal hypertension (9, 10) . However, whether HJBs appear following partial splenic embolization (PSE) has not been investigated to date. Therefore, we examined the prevalence of HJBs in patients who have undergone PSE.
Materials and Methods
This was a retrospective study conducted using prospectively collected data obtained from patients who underwent Co., Ltd., Tokyo, Japan) was selectively inserted into each of the vessels, and embolization using coils and 2-mm 2 gelatin sponges soaked with 20 mg of gentamicin (Gentacin; Merck & Co., Inc., Whitehouse Station, NJ, USA) was performed, as previously reported (11) . The goal was to achieve infarction of approximately two-thirds of the entire spleen. Antibiotics were administered via peripheral intravenous infusion for five days after the procedure, and oral nonsteroidal anti-inflammatory drugs (NSAIDs) were given as needed for fevers ! 38 . Contrast CT was performed one week after PSE to confirm the extent of splenic infarction and detect the presence of any abscess formation or portal vein thrombosis. The study protocol conformed to the Declaration of Helsinki of 1975. Table 1 shows the clinical characteristics of the 95 patients. The mean Child-Pugh score was 7.58±1.84 before PSE. The mean splenic infarction rate was 51.85%±17.09%. The mean platelet count increased significantly two weeks after PSE from 7.20×10 4 ±3.25×10 4 /μL to 12.08×10 4 ±7.22× 10 4 /μL. Six months after PSE, the mean platelet count decreased to 10.51×10 4 ±4.3×10 4 /μL, although it remained higher than that observed before PSE.
Results
The common PSE complications included fever in 48 patients (50.5%) and abdominal pain in 30 patients (31.5%). Jaundice worsened in four patients (4.2%) with a liver function of class C (according to the Child-Pugh classification).
Twelve patients (12.6%) developed areas of pleural effusion and ascites; however, there were no serious complications, such as splenic abscess formation or portal vein thrombosis. No patients developed OPSI or PSS.
HJBs were present in 17 of the 95 patients (17.89%). A representative case of HJBs is shown in Figure. A comparison of the clinical characteristics between the HJB-positive and HJB-negative patients revealed no significant differences, including the residual spleen volume, splenic infarction rate and Child Pugh score before PSE (Table 2) . Table 3 shows the clinical characteristics of the 17 HJBpositive patients. HJBs were present in a high rate of patients with type C liver cirrhosis (10/48, 20.8%). PSE was performed as pretreatment before the initiation of interferon (IFN) therapy for type C liver cirrhosis. In such cases, caution is required because immunosuppression can occur during subsequent IFN therapy. HJBs were also detected in three patients with alcoholic cirrhosis, two patients with primary biliary cirrhosis (PBC) and two patients with metastatic liver cancer. As HJBs were seen in two of the three patients receiving chemotherapy for metastatic liver cancer, anticancer drugs also had an impact on immunosuppression. None of the 11 patients with type B liver cirrhosis had HJBs.
Discussion
The spleen contains approximately 25% of all lymphoid tissue in the body. With regard to the immune function, the spleen serves as an effective filter for bacteria using phagocytosis in the splenic sinusoids, exhibits opsonic effects via the production of IgM antibodies and produces factors that regulate the complement system. The spleen is the only peripheral immune organ with marginal zone B cells, while lymph nodes, typical peripheral immune organs, do not have marginal zone B cells.
Marginal zone B cells produce immunoglobulin M (IgM) antibodies against bacterial capsular polysaccharides. Therefore, if the splenic function is impaired, susceptibility to bacteria, for which anticapsular polysaccharide IgM is an essential factor in biological defense, is markedly increased (12, 13) . Pneumococcus, H. influenzae and meningococcus express capsular polysaccharides and can therefore escape the phagocytosis of host phagocytic cells (14) . As a result, these bacteria spread throughout the body from sites of local infection, which can lead to serious infections, such as meningitis and septicemia. The morbidity rate due to infection with pneumococcus is particularly high.
In healthy persons with a normal spleen function, IgM against capsular polysaccharides acts on the capsule to prevent escape from the phagocytosis of phagocytic cells. Consequently, rapid phagocytosis, bactericidal actions and healing of infection occur without the development of serious sequelae. In asplenic or postsplenectomy patients, bacterial infections can easily become more severe. Splenectomy and PSE have recently received attention as treatment for portal hypertension associated with thrombocytopenia. Splenectomy is thought to be superior to PSE in increasing the platelet count; however, portal vein thrombosis and OPSI caused by pneumococcus infection remain problems (15) . OPSI has a high mortality rate and a poor prognosis (16, 17) . It is usually diagnosed in patients with fulminant infections, and serious, possibly fatal, infection can develop a second time, even after an initial recovery. Antibiotic prophylaxis and the pneumococcal vaccine are administered to prevent bacterial infections; however, when infection occurs, the administration of aggressive antibiotic therapy is essential in order to improve the prognosis of OPSI.
It has long been known that splenectomy can lead to immunosuppression and an increased susceptibility to infections (18) . Therefore, in order to prevent OPSI, administering the pneumococcal vaccine in postsplenectomy patients is recommended (17) .
On the other hand, the absence of a significant relationship between hyposplenism and infection in patients with liver cirrhosis has also been reported (19) . As a background factor, the use of splenectomy in patients with liver cirrhosis is reported to improve the T1/T2 balance and achieve antitumor effects (20) . Since splenectomy also significantly improves leukopenia and neutropenia, the use of splenectomy in cirrhotic patients may improve the immune function (21) .
Maddison first reported splenic embolization as a treatment for hypersplenism in 1973 (22) . However, this procedure resulted in a high incidence of serious complications, including splenic rupture and abscess formation, and was not widely adopted. In 1979, Spigos et al. reported the use of PSE in association with antibiotic prophylaxis, with the goal of achieving embolization of approximately two-thirds of the spleen (10) .
PSE became widely adopted following the publication of that report. Like splenectomy, PSE is primarily indicated to treat portal hypertension, achieve decompression of portal pressure in gastrointestinal varices and improve pancytopenia as a preliminary treatment before surgery or systemic chemotherapy. However, the need for pretreatment before the initiation of combined interferon/ribavirin therapy in type C hepatitis patients with thrombocytopenia has recently increased, and attention has focused on the clinical utility of PSE. HJBs are present in a high rate of type C liver cirrhosis patients, although no hepatitis patients have HBJs. Proof of this phenomenon has not been published, and further investigations are thus needed to determine whether immunological factors are involved. PSE not only improves hypersplenism, but also contributes to reducing the portal pressure and increasing the serum albumin level. In this sense, PSE improves the hepatic functional reserve and may also improve the immune function, although a reduction in the spleen volume may lead to hyposplenism. The extent of splenic embolization differs among medical centers. With PSE, as with splenectomy, there is a risk of OPSI.
The present study found no relationships between the rate of splenic infarction and the presence of HJBs. However, PSE can induce an asplenic state, irrespective of the infarction rate. The presence of HJBs on peripheral blood smears is reported to be useful for assessing the splenic function (8, 23, 24) . When HLBs are present, the pneumococcal vaccine should be administered immediately in order to prevent OPSI and PSS.
In this study, although no fatal complications occurred following PSE, 17 of the 95 patients (17.89%) developed HJBs during the follow-up.
In conclusion, the presence of HJBs after PSE may indicate a severe decrease in the splenic function. As with splenectomy, there is also a risk of OPSI following PSE. Therefore, the presence or absence of HJBs in peripheral erythrocytes must be assessed visually in patients who have undergone PSE. The presence of HBJs following PSE indicates a possibly severe condition, and the pneumococcal vaccine should be administered immediately to prevent OPSI and PSS.
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